Long-term proton pump inhibitor therapy in daily clinical practice – balancing benefits and potential risks: a narrative review.
Abstract
Background and Aim
The introduction of proton pump inhibitors (PPIs) in the late 1980s revolutionized the management of acid-related diseases. However, their high efficacy and favorable safety profile have led to widespread overprescribing, with an estimated 30–50% of primary care patients taking them without clear clinical indications. This review aims to critically summarize the current state of medical knowledge regarding the clinical benefits, long-term multi-organ risks, and principles of safe PPI discontinuation based on contemporary clinical guidelines.
Methods
A comprehensive review of current medical literature and official guidelines from major scientific organizations (including the American Gastroenterological Association [AGA], and the American College of Gastroenterology [ACG] concerning indications, complications, and PPI deprescribing protocols was performed.
Results
Chronic PPI therapy is justified in severe gastroesophageal reflux disease (GERD grades C and D according to the Los Angeles classification), Barrett’s esophagus (for chemoprevention of high-grade dysplasia and adenocarcinoma), hypersecretory states (e.g., Zollinger-Ellison syndrome), and gastroprotection during NSAID or anticoagulant therapy in high-risk patients. Nonetheless, prolonged acid suppression (iatrogenic hypochlorhydria) is associated with significant systemic complications. These include nutritional deficiencies (vitamin B12, iron, magnesium, calcium), progressive bone demineralization (osteoporosis and low-energy fractures), increased susceptibility to infections (C. difficile, [SIBO], community-acquired pneumonia [CAP], subclinical renal injury (acute interstitial nephritis [AIN] leading to chronic kidney disease [CKD], fundic gland polyps [FGP], and drug-drug interactions (e.g., with clopidogrel or levothyroxine). The process of deprescribing is often hindered by Rebound Acid Hypersecretion [RAHS], which simulates a recurrence of the primary disease, prompts patients to resume medication, and establishes a clinical “vicious cycle”.
Conclusions
Modern clinical care for patients on long-term PPI therapy demands regular re-evaluation of treatment indications. If long-term therapy is no longer justified, a structured de-escalation plan consisting of gradual dose reduction (tapering), extension of dosing intervals, and transition to on-demand therapy is required to mitigate chronic risks and prevent RAHS symptoms.
© 2026 Paulina Głowacka, Aleksandra Bartkowska, Paulina Orzechowska, Gabriela Mastej-Witek, Alicja Okupniak, Gabriela Budziszewska, Mateusz Nieczyporuk, Aneta Dziurdź, Aleksandra Łupicka, Monika Ziemba, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.